# Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

Source: https://onco.cc/trials/nct05802225/  
OnCo record `nct05802225` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pertuzumab in HER2-positive breast cancer, run by Biocad, active and no longer recruiting.

## Summary

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer is a phase 3 interventional study registered as NCT05802225 by Biocad, with 398 participants enrolled, started 2023-01-30 and due to reach its primary completion in 2025-06-06. Interventions recorded: BCD-178 and Perjeta.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05802225
- Phase: 3
- Setting: A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
- Sponsor: Biocad
- Enrolled: 398

## Sources

- ClinicalTrials.gov NCT05802225: https://clinicaltrials.gov/study/NCT05802225

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Pertuzumab](https://onco.cc/drugs/pertuzumab/)
- companies: [Biocad](https://onco.cc/companies/biocad/)

---
JSON: https://onco.cc/api/v1/entities/nct05802225.json